Photo: Associate editor Kyle LaHucik for Endpoints News
#ASH22 roundup: CSL shows two years of data in $3.5M hemophilia gene therapy; Syndax shows 30% CR rate from March data cut
NEW ORLEANS — CSL Behring made headlines last month after the FDA gave approval to the biotech for its hemophilia B gene therapy with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
